4:21 PM
 | 
Aug 29, 2013
 |  BC Extra  |  Top Story

Priority Review for Pharmacyclics' ibrutinib

FDA accepted and granted Priority Review to an NDA from Pharmacyclics Inc. (NASDAQ:PCYC) for ibrutinib to treat relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small cell lymphocytic...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >